View Older Stories

Dec 31, 2025 06:32AM Mizuho Reiterates Outperform Rating on Verastem (VSTM)

Dec 15, 2025 04:01PM Verastem Oncology names new chairman, president of development

Nov 5, 2025 10:03AM Verastem (VSTM) PT Raised to $14 at RBC Capital; 'Stock Is Oversold'

Nov 4, 2025 07:59AM Verastem Oncology (VSTM) Misses Q3 EPS by 54c

Oct 21, 2025 10:08AM Mizuho Reiterates Outperform Rating on Verastem (VSTM)

Oct 21, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

Oct 20, 2025 07:40AM Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM) on Dual-Program Growth Potential

Oct 16, 2025 06:24AM Cantor Fitzgerald Assumes Verastem (VSTM) at Overweight

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Aug 18, 2025 06:36AM Verastem (VSTM) PT Lowered to $14 at Mizuho

Aug 14, 2025 05:33AM BTIG Reiterates Buy Rating on Verastem (VSTM)

Aug 13, 2025 04:29PM Verastem partner reports 68.8% response rate for lung cancer drug in China study

Aug 8, 2025 08:48AM Verastem Oncology (VSTM) Files $300M Mixed Shelf

Jul 24, 2025 07:30AM Verastem gets fast track status for pancreatic cancer drug VS-7375

Jul 11, 2025 04:12PM Verastem publishes phase 2 trial results in Journal of Clinical Oncology

Jul 1, 2025 12:33PM BTIG on Verastem (VSTM): '2H25 Top Pick'

Jun 30, 2025 04:02PM Verastem Oncology (VSTM) announces publication of results from Phase 1 FRAME study

Jun 24, 2025 04:02PM Verastem Oncology (VSTM) Announces First Patient Dosed with VS-7375 in U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 3, 2025 07:08AM Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM)

Jun 2, 2025 09:40AM Verastem Oncology (VSTM) Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375

May 22, 2025 05:07PM Verastem Oncology (VSTM) announces positive results from phase 1/2 trial on Avutometinib plus Defactinib

May 20, 2025 08:33AM Tempus AI (TEM) Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 13, 2025 06:27PM Verastem Oncology (VSTM) Misses Q1 EPS by 79c

May 8, 2025 01:44PM Verastem (VSTM) PT Raised to $19 at Jefferies

May 8, 2025 11:47AM Verastem, Avmapki Fakzynja combination of avutometinib and defactinib approved by FDA

Apr 29, 2025 06:28AM Mizuho on Verastem (VSTM): 'we continue to favor it as a top small cap biotech idea'

Apr 25, 2025 09:00AM Verastem Oncology (VSTM) Prices $75M Share Offering at $7/sh

Apr 23, 2025 04:08PM Verastem Oncology (VSTM) Announces U.S. IND Clearance of VS-7375

Apr 10, 2025 03:34AM Jefferies Starts Verastem (VSTM) at Buy

Mar 24, 2025 07:26AM Verastem (VSTM) PT Raised to $14 at Guggenheim

Mar 24, 2025 06:40AM Verastem (VSTM) PT Raised to $10 at H.C. Wainwright

Mar 21, 2025 06:33AM BTIG Reiterates Buy Rating on Verastem (VSTM)

Jan 24, 2025 08:22AM Mizuho Reiterates Outperform Rating on Verastem (VSTM), Says 'Poised for a Breakout in 2025'

Jan 23, 2025 07:31AM Verastem Oncology (VSTM) Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 16, 2025 06:04AM BTIG Reiterates Buy Rating on Verastem (VSTM)

Jan 15, 2025 07:30AM Verastem Oncology (VSTM) Appoints Matthew E. Ros as COO

Jan 14, 2025 07:31AM Verastem Oncology (VSTM) Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA

Jan 13, 2025 07:31AM Verastem Oncology (VSTM) Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA

Dec 30, 2024 11:27PM Verastem (VSTM) PT Raised to $20 at BTIG

Dec 30, 2024 04:32PM Verastem Oncology (VSTM) Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib

Dec 30, 2024 02:29PM B.Riley Reiterates Buy Rating on Verastem (VSTM)

Dec 20, 2024 07:01AM Applied Therapeutics Inc. (APLT) Appoints John H. Johnson as Executive Chairman

Dec 19, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

Dec 18, 2024 07:31AM Verastem Oncology (VSTM) Provides a Clinical Update for RAMP 203 Trial

Dec 18, 2024 06:28AM Verastem (VSTM) PT Raised to $9 at Mizuho

Oct 17, 2024 01:40PM Verastem (VSTM) defended at Truist, 'see the weakness as an overreaction and continue to see commercial potential'

Aug 13, 2024 07:13AM Verastem (VSTM) PT Lowered to $15 at Truist Securities

Aug 12, 2024 06:54AM Verastem (VSTM) PT Lowered to $7 at H.C. Wainwright

Aug 8, 2024 06:16PM Verastem Oncology (VSTM) Misses Q2 EPS by 61c

View Older Stories